158985-36-5

Basic information

• Product Name: 1-Boc-4-(4-methoxycarbonylphenyl)piperazine
• Synonyms: TERT-BUTYL 4-[4-(METHOXYCARBONYL)PHENYL]TETRAHYDRO-1(2H)-PYRAZINECARBOXYLATE;1-BOC-4-(4-METHOXYCARBONYLPHENYL)PIPERAZINE;4-(4-METHOXYCARBOXYPHENYL)PIPERAZINE-1-CARBOXYLIC ACID TERT-BUTYL ESTER;4-[4-(METHOXYCARBONYL)PHENYL]-1-PIPERAZINECARBOXYLIC ACID, 1,1-DIMETHYLETHYL ESTER;METHYL 4-(BOC-PIPERAZIN-1-YL)-BENZOATE;BUTTPARK 99\06-01;tert-Butyl 4-[4-(methoxycarbonyl)phenyl]piperazine-1-carboxylate;1-BOC-4-(4-METHOXYCARBONYLPHENYL)PIPERA&
• CAS NO: 158985-36-5
• Molecular Formula: C₁₇H₂₄N₂O₄
• Molecular Weight: 320.38
• Product Categories: API intermediates;piperazines;Building Blocks;C16 to C29;Chemical Synthesis;Heterocyclic Building Blocks
• Mol File: 158985-36-5.mol
• Article Data: 14

Chemical Properties

• Melting Point: 166-170 °C(lit.)
• Boiling Point: 451.7°Cat760mmHg
• Flash Point: 227°C
• Appearance: /
• Density: 1.153g/cm³
• Vapor Pressure: 2.38E-08mmHg at 25°C
• Refractive Index: 1.535
• CAS DataBase Reference: 1-Boc-4-(4-methoxycarbonylphenyl)piperazine(CAS DataBase Reference)
• NIST Chemistry Reference: 1-Boc-4-(4-methoxycarbonylphenyl)piperazine(158985-36-5)
• EPA Substance Registry System: 1-Boc-4-(4-methoxycarbonylphenyl)piperazine(158985-36-5)

Safety Data

• Hazard Codes: T
• Statements: 25-52/53
• Safety Statements: 45
• RIDADR: UN 2811 6.1/PG 3
• WGK Germany: 2
• Hazardous Substances Data: 158985-36-5(Hazardous Substances Data)

Usage

General Description

1-Boc-4-(4-methoxycarbonylphenyl)piperazine is a chemical compound with the molecular formula C18H26N2O4. It is a derivative of piperazine and contains a 4-(4-methoxycarbonylphenyl) moiety attached to the piperazine ring. The compound has a tert-butoxycarbonyl (Boc) protecting group on the nitrogen atom of the piperazine ring. 1-Boc-4-(4-methoxycarbonylphenyl)piperazine is used as an intermediate in the synthesis of pharmaceuticals and other organic compounds. It may also have potential applications in medicinal chemistry and drug development due to its structural features and pharmacological properties.

InChI:InChI=1/C17H24N2O4/c1-17(2,3)23-16(21)19-11-9-18(10-12-19)14-7-5-13(6-8-14)15(20)22-4/h5-8H,9-12H2,1-4H3

Upstream product

• 163210-97-7 methyl 4-(piperazin-1-yl)benzoate 
• 24424-99-5 di-tert-butyl dicarbonate 
• 619-42-1 4-methoxycarbonylphenyl bromide 
• 57260-71-6 1-t-Butoxycarbonylpiperazine 
• 619-44-3 methyl 4-iodobenzoate 
• 403-33-8 methyl 4-flurobenzoate 
• 619-45-4 4-methoxycarbonyl aniline 
• 3375-31-3 palladium diacetate 

Downstream Products

• 162046-66-4 4-(4-(1,1-dimethylethoxycarbonyl)piperazin-1-yl)benzoic acid 
• 1447331-89-6 {6-[4-(4-boc-piperazin-1-yl)benzoylamino]-1-oxo-1,3-dihydroisoindol-2-yl}acetic acid 
• 1447330-19-9 [1-oxo-6-(4-piperazinium-1-yl-benzoylamino)-1,3-dihydroisoindol-2-yl]acetic acid trifluoroacetate 
• 1447331-32-9 {6-[4-(4-boc-piperazin-1-yl)benzoylamino]-1-oxo-1,3-dihydroisoindol-2-yl}acetic acid methyl ester 

Relevant articles and documents

Discovery of a Potent FLT3 Inhibitor (LT-850-166) with the Capacity of Overcoming a Variety of FLT3 Mutations

Secondary mutations of FLT3 have become the main mechanism of FLT3 inhibitor resistance that presents a significant clinical challenge. Herein, a series of pyrazole-3-amine derivatives were synthesized and optimized to overcome the common secondary resistance mutations of FLT3. The structure-activity relationship and molecular dynamics simulation studies illustrated that the ribose region of FLT3 could be occupied to help address the obstacle of secondary mutations. Among those derivatives, compound 67 exhibited potent and selective inhibitory activities against FLT3-ITD-positive acute myeloid leukemia (AML) cells and possessed equivalent potency against transformed BaF3 cells with a variety of secondary mutations. Besides, cellular mechanism assays demonstrated that 67 strongly inhibited phosphorylation of FLT3 and its downstream signaling factors, as well as induced cell cycle arrest and apoptosis in MV4-11 cells. In the MV4-11 xenograft models, 67 exhibited potent antitumor potency without obvious toxicity. Taken together, these results demonstrated that 67 might be a drug candidate for the treatment of FLT3-ITD-positive AML.

PYRAZOLOTRIAZOLOPYRIMIDINE DERIVATIVES AS A2A RECEPTOR ANTAGONIST

Disclosed herein is a pyrazolotriazolopyrimidine derivative or a stereoisomer thereof, or a pharmaceutically acceptable salt thereof useful as A2A receptor antagonist, and a pharmaceutical composition comprising the same. Also disclosed herein is a method of treating cancer using the pyrazolotriazolopyrimidine derivative or a stereoisomer thereof, or a pharmaceutically acceptable salt thereof as A2A receptor antagonist.

SELECTIVE HDAC1,2 INHIBITORS

Provided herein are compounds, pharmaceutical compositions comprising such compounds, and methods of using such compounds to treat diseases or disorders associated with HDAC1 and/or HDAC2 activity.